Patents Represented by Attorney, Agent or Law Firm Janis C. Henry
-
Patent number: 7138500Abstract: Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and host cells transformed with the recombinant expression vectors are disclosed, along with methods for producing the novel polypeptides by cultivating such transformed host cells. Soluble forms of the 4-1BB-L or 4-1BB polypeptides are derived from the extracellular domains thereof.Type: GrantFiled: September 10, 1998Date of Patent: November 21, 2006Assignee: Immunex CorporationInventors: Raymond G. Goodwin, Craig A. Smith, Mark R. Alderson
-
Patent number: 7129203Abstract: Processes for conjugating proteins with polyethylene glycol are disclosed. The disclosed processes provide modified proteins having little or no decrease in their activity and include the steps of deleting at least one amino acid residue on the protein, replacing the at least one amino acid residue with an amino acid residue that does not react with polyethylene glycol, and contacting the protein with polyethylene glycol under conditions sufficient to conjugate the polyethylene glycol to the protein. This advantageous retention of a desired protein activity is attributed to the availability of one or more protein binding sites which is unaltered in the conjugation process and thus remains free to interact with a binding partner ligand or cognate subsequent to the conjugation process.Type: GrantFiled: September 12, 2002Date of Patent: October 31, 2006Assignee: Immunex CorporationInventor: Dean K. Pettit
-
Patent number: 7049095Abstract: DNA encoding IL-1R AcP splice variant polypeptides, the polypeptides and methods for using the encoded polypeptides are disclosed.Type: GrantFiled: October 26, 2001Date of Patent: May 23, 2006Assignee: Immunex CorporationInventors: John E. Sims, Dirk E. Smith
-
Patent number: 7001599Abstract: 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.Type: GrantFiled: May 28, 2002Date of Patent: February 21, 2006Assignee: Immunex CorporationInventors: Patricia Parnet, John E. Sims
-
Patent number: 6887684Abstract: There are disclosed MAL-1 polypeptides and active fragments of MAL-1, including fragments that associate with IRAK2. Further disclosed are DNAs encoding the polypeptides and fragments as well as methods of using the DNAs and polypeptides.Type: GrantFiled: May 17, 2001Date of Patent: May 3, 2005Assignee: Immunex CorporationInventors: John E. Sims, Timothy A. Bird, Luke A. J. O'Neill
-
Patent number: 6774224Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: August 5, 2002Date of Patent: August 10, 2004Assignee: Immunex CorporationInventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
-
Patent number: 6753166Abstract: The invention is directed to novel, purified and isolated IL-1 eta polypeptides and fragments thereof, the polynucleotides encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, peptides derived from these polypeptides, and uses thereof.Type: GrantFiled: October 11, 2001Date of Patent: June 22, 2004Assignee: Immunex CorporationInventors: John E. Sims, Blair R. Renshaw
-
Patent number: 6692740Abstract: The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: GrantFiled: August 2, 2002Date of Patent: February 17, 2004Assignee: Immunex CorporationInventors: John E. Sims, Teresa L. Born
-
Patent number: 6693171Abstract: The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: GrantFiled: August 2, 2002Date of Patent: February 17, 2004Assignee: Immunex CorporationInventors: John E. Sims, Teresa L. Born
-
Patent number: 6680057Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.Type: GrantFiled: April 14, 2000Date of Patent: January 20, 2004Assignee: Immunex CorporationInventors: Zhengbin Yao, Melanie K. Spriggs, William C. Fanslow
-
Patent number: 6670135Abstract: This invention provides a method comprising assaying the binding of a DCSema polypeptide to a VESPR protein.Type: GrantFiled: October 12, 2000Date of Patent: December 30, 2003Assignee: Immunex CorporationInventor: Melanie K. Spriggs
-
Patent number: 6664077Abstract: The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: GrantFiled: July 14, 2000Date of Patent: December 16, 2003Assignee: Immunex CorporationInventors: John E. Sims, Teresa L. Born
-
Patent number: 6653447Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: March 13, 2000Date of Patent: November 25, 2003Assignee: Immunex CorporationInventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
-
Patent number: 6613320Abstract: CD4+ cells obtained from individuals with defective CD40L gene and transfected with a vector containing CD40-L are described.Type: GrantFiled: April 10, 2000Date of Patent: September 2, 2003Assignee: Immunex CorporationInventors: Melanie K. Spriggs, Richard J. Armitage, William C. Fanslow, III, Michael B. Widmer, Barry L. Davison, Blair R. Renshaw
-
Patent number: 6589764Abstract: A polypeptide that functions as an IL-18 receptor is disclosed. The receptor is multimeric and includes at least one AcPL polypeptide, or fragment thereof, and at least one IL-1Rrp1 polypeptide, or fraction thereof. The receptor binds IL-18 and finds use in inhibiting biological activities mediated by IL-18.Type: GrantFiled: July 21, 2000Date of Patent: July 8, 2003Assignee: Immunex CorporationInventors: John E. Sims, Teresa L. Born
-
Patent number: 6548644Abstract: Processes for conjugating proteins with polyethylene glycol are disclosed. The disclosed processes provide modified proteins having little or no decrease in their activity and include the steps of protecting one or more sites on the protein, contacting the protected protein with polyethylene glycol under conditions suitable for conjugating the polyethylene glycol to the protein, and deprotecting the protein. This advantageous retention of a desired protein activity is attributed to the availability of one or more protein binding sites which is unaltered in the conjugation process and thus remains sterically free to interact with a binding partner ligand or cognate subsequent to the conjugation process.Type: GrantFiled: March 10, 1997Date of Patent: April 15, 2003Assignee: Immunex CorporationInventor: Dean K. Pettit
-
Patent number: 6524817Abstract: A novel polypeptide functions as the &bgr; chain of an oncostatin M receptor and is thus designated OSM-R&bgr;. Heterodimeric receptor proteins comprising OSM-R&bgr; and gp130 bind oncostatin M and find use in inhibiting biological activities mediated by oncostatin M.Type: GrantFiled: December 6, 1999Date of Patent: February 25, 2003Assignee: Immunex CorporationInventors: Bruce Mosley, David J. Cosman
-
Patent number: 6521740Abstract: Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed.Type: GrantFiled: May 16, 1995Date of Patent: February 18, 2003Assignee: Immunex CorporationInventors: John E. Sims, David J. Cosman, Stephen D. Lupton, Bruce A. Mosley, Steven K. Dower
-
Patent number: 6511665Abstract: The present invention provides monoclonal antibodies and binding proteins which specifically bind to the IL-1 receptor. Also provided are methods for detecting IL-1 receptors on cells, and for detecting soluble IL-1 receptors in serum.Type: GrantFiled: May 30, 1995Date of Patent: January 28, 2003Assignee: Immunex CorporationInventors: Steven K. Dower, Carl J. March, John E. Sims, David L. Urdal
-
Patent number: 6504023Abstract: Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed.Type: GrantFiled: December 13, 1999Date of Patent: January 7, 2003Assignee: Immunex CorporationInventors: John E. Sims, David J. Cosman, Stephen D. Lupton, Bruce A. Mosley, Steven K. Dower